Secondary endpoints included

Related by string. * secondary . SECONDARY . Secon dary : Secondary Offering . Secondary School . secondary efficacy endpoints / Endpoints . EndPoint . Endpoint : Secondary endpoints include . primary efficacy endpoint . video conferencing endpoints / incl uding . Included . Including : Including Packer Sold Barrows . INCLUDING BUT NOT LIMITED . INCLUDING WITHOUT LIMITATION CONSEQUENTIAL * *

Related by context. Frequent words. (Click for all words.) 86 Secondary endpoints include 76 Secondary endpoints 69 secondary endpoint 66 P = .# 66 achieved statistical significance 66 secondary endpoints 65 CI -#.# 65 p = #.# [004] 65 placebo p = 65 mg QD 65 secondary efficacy endpoints 65 demonstrated statistically significant 65 primary efficacy endpoint 64 ADAS cog 64 biochemical recurrence 64 patients evaluable 64 p = #.# [002] 63 evaluable 63 % CI #.#-#.# [003] 63 placebo p 63 Negative Syndrome 63 PANSS 63 #mg/day [001] 63 confidence interval CI 63 primary endpoint 62 prespecified 62 histologic 62 μg kg 62 confidence interval #.#-#.# 62 statistically significant improvement 62 Global Impression 62 cytogenetic response 62 Postoperative 62 composite endpoint 61 CI #.#-#.# [002] 61 % CI #.#-#.# [007] 61 irbesartan 61 chlorambucil 61 plus methotrexate 61 mucosal healing 61 Main Outcome Measures 61 p = 61 IPSS 61 plus prednisone 61 annualized relapse 60 tumor lysis syndrome 60 Thrombolysis 60 subscales 60 QTc 60 mg BID 60 ACR# response 60 nonsignificant 60 RECIST criteria 60 primary endpoints 60 Unified Parkinson Disease 60 estimated glomerular filtration 60 thromboembolic events 60 apolipoprotein B 60 free survival PFS 59 statistically significant p 59 59 XIENCE V vs. 59 univariate 59 complete cytogenetic 59 % CI #.#-#.# [006] 59 surrogate endpoint 59 univariate analysis 59 statistically significant p = 59 Preoperative 59 mitoxantrone 59 fasting insulin 59 concomitant medications 59 coronary revascularization 58 Cmax 58 Pharmacokinetic 58 pharmacokinetic profiles 58 mcg kg 58 carotid intima media 58 preoperatively 58 fasting plasma glucose 58 ventilatory 58 fibrinolysis 58 distant metastasis 58 plus gemcitabine 58 cerebrovascular events 58 tumor resection 58 Disease Activity 58 HbA 1c 58 Natalizumab 58 n = 58 symptom severity 57 primary efficacy endpoints 57 sensitivity specificity 57 pulmonary vascular 57 left ventricular systolic 57 nab paclitaxel 57 plus dexamethasone 57 chemoradiotherapy 57 WOMAC 57 hypoglycemic events 57 lamotrigine

Back to home page